van family medical semaglutide Is a GLP-1 Medication Right for You? 5 Questions to Ask Before You Start » Lawrenceville Practice Compounded Semaglutide - Medical Weight

Whether this increases or decreases oral dryness compared to injections is not yet well studied

The first to be approved for this indication was liraglutide (Saxenda) in 2014, followed by semaglutide (Wegovy) in 2021 and tirzepatide (Zepbound

Collaboration across disciplines and leveraging advanced technologies will be key to advancing our understanding and optimizing patient care

GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, including semaglutide, dulaglutide, and liraglutide These medications reduce HbA1c by approximately 1.01.5 percentage points and improve both fasting and post-meal glucose levels Weight loss associated with GLP-1 therapy can lead to secondary improvements in insulin resistance, particularly through reduction of visceral fat Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, which typically diminish over several weeks NICE recommends continuation only if patients achieve at least 1.0 percentage point HbA1c reduction within six months of treatment initiation Patients with diabetic retinopathy require close monitoring, and GLP-1 medications should be discontinued at least two months before planned pregnancy Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work